Elevated TNF-α and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis

Pathology Research and Practice

Volumn 204, Issue 2, 2008, Pages 129-132

  Jurisic, Vladimir ^c   Terzic, Tatjana ^a,b   Pavlovic, Sonja ^d   Colovic, Natasa ^a   Colovic, Milica ^a  

^a University Clinical Center   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

^d Institute for Molecular Genetics and Genetic Engineering   (Serbia)

Author keywords

Diffuse osteolyses; LDH; Leukemic transformation; Myelofibrosis; TNF

Indexed keywords

ANTIBIOTIC AGENT; CD14 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; COLLAGEN; CYTARABINE; CYTOKINE; HLA DR ANTIGEN; HYDROXYUREA; LACTATE DEHYDROGENASE; MICROSOMAL AMINOPEPTIDASE; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLEEDING; BLOOD ANALYSIS; BLOOD SMEAR; BONE LESION; CANCER SURVIVAL; CASE REPORT; CHROMOSOME 16P; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; DACRYOCYSTITIS; DISEASE ASSOCIATION; DRUG FEVER; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; MYELOPHTHISIC ANEMIA; MYELOPROLIFERATIVE DISORDER; OSTEOLYSIS; OSTEOSCLEROSIS; PANCYTOPENIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY;

EID: 38849145096     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.09.001     Document Type: Article

References (15)

1. Azuma T., Sakai I., Matsumoto T., Ozawa A., Tanji N., Watanabe A., Uchida N., Narumi H., Yakuschijin Y., Hato T., Yakusawa M., and Fujita S. Leukemoid reaction in association with bone marrow necrosis due to metastatic prostate cancer. Intern. Med. 44 (2005) 1093-1096
2. Bock O., Loch G., Schade U., Von Wasielewski R., Schlue J., and Kreipe H. Aberran expression of transforming growth factor β-1 (TGF-β1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J. Pathol. 205 (2005) 548-557
3. Colovic M., Jankovic G., Suvajdzic N., and Colovic R. Acute myeloid leukemia evolving from haemorrhagic essential thrombocythemia. Eur. J. Haematol. 280 (1998) 61-62
4. Colovic M., Jankovic G., Bila J., Djordjevic V., and Wiernik P.H. Inversion of chromosome 16 in accelerated phase of chronic myeloid leukemia: report of a case and rewiew of the literature. Med. Oncol. 15 (1998) 199-201
5. Colovic M., Wiernik P.H., Jankovic G., Vidovic A., Janosevic S., and Basara N.M. Circulation haematopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. Eur. J. Haematol. 62 (1999) 155-159
6. Hernandez J.M., San Miguel J.F., Gonzalez M., Orfao A., Canizo M.C., and Bascones C.J. Development of acute leukemia after idiopathic myelofibrosis. Clin. Pathol. 45 (1992) 427-430
7. Jurisic V., and Colovic M. Correlation of sera TNF-alpha activity with percentage of bone marrow plasma cells, LDH, beta-2 miroglobulines, and clinical stage in multiple myeloma. Med. Oncol. 19 (2002) 133-139
8. Jurisic V., Spuzic I., and Konjevic G. A comparison of NK cell activity with effects of TNF-α against K-562 cells, determined by LDH release assay. Cancer Lett. 138 (1999) 67-72
9. Jurisic V., Bogdanovic G., Srdic T., Jakimov D., Mrdjanovic J., Baltic M., and Baltic V.V. Modulation of TNF-α activity in tumor PC cells using anti-CD45 and anti CD95 monoclonal antibody. Cancer Lett. 214 (2004) 55-61
10. Jurisic V., Bogdnovic G., Kojic V., Jakimov D., and Srdic T. TNF-α effects on Raji cells at different cellular level estimated by various methods. Ann. Hematol. 85 (2006) 86-94
11. Kosmidis P.A., Palacas Ch.G., and Axelrod A. Diffuse purely osteolytic lesions in myelofibrosis. Cancer 46 (1980) 2263-2265
12. Kumar S., Mow B.M.F., and Kaufmann S.H. Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis. Mayo Clin. Proc. 74 (1999) 1233-1237
13. Lima S.C., Pinto Neto J.V., Da Cunha M.A., Vassallo J., Cardinalli I.A., and De-Souza C.A. Osteolytic lesions as a presenting sign of acute myeloid leukemia. Haematologia 40 (2000) 325-331
14. Steensma D.P., Messa R.A., Li C.Y., and Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of pilot study. Blood 99 (2002) 2252-2254
15. Tricot G., Boogaerts M.A., Broceckaert-Van Orshoven A., Criel A., Van Hoof A., and Van de Berghe H. Hypercalcemia and diffuse osteolytic lesions in the acute phase of chronic myelogenous leukemia. Cancer 52 (1983) 841-845